SARCOPENIC DIABETES IS AN UNDER-RECOGNIZED AND UNMET CLINICAL PRIORITY. A CALL FOR ACTION FROM THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM AND THE DIABETES NUTRITION STUDY GROUP

Descargar Publicación
Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions Metabolic Syndrome and Risk of New-Onset Type 2 Diabetes Mellitus: An Eight-Year Follow-Up Study in Southern Israel